Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
NuCana plc
Providence Health & Services
Shanghai Junshi Bioscience Co., Ltd.
Amphia Hospital
Tianjin Medical University Cancer Institute and Hospital
National Cancer Centre, Singapore
ASLAN Pharmaceuticals
UNC Lineberger Comprehensive Cancer Center
Ziekenhuis Oost-Limburg
SCRI Development Innovations, LLC
NYU Langone Health
University of Pittsburgh
University of Pittsburgh
Barbara Ann Karmanos Cancer Institute
Northwestern University
Mayo Clinic